|Britain Has No Problem Paying for Expensive Hepatitis C Drugs|
Sovaldi, a highly effective treatment for the liver disease hepatitis C, has faced backlash in the U.S. over its price tag: $84,000 for a three-month course of treatment, or about $1,000 a pill. The private insurance industry has pushed back hard on ...
Businessweek - Mon, 18 Aug 2014 09:36
|UK's NICE Recommends Gilead's Sovaldi For Hepatitis C|
Pharmaceutical Online (press release) - Mon, 18 Aug 2014 08:22
|Under the radar: the silent grip of Hepatitis C|
Hepatitis C, a viral disease that affects the liver, is four times more common than the HIV virus. Around the world, 170 million people are infected with it. Between 20,000 and 50,000 people in the Republic of Ireland are estimated to have hepatitis C ...
Irish Times - Mon, 18 Aug 2014 17:03
|Hepatitis C investigation ongoing|
Previously: Clark County Public Health and PeaceHealth Southwest Medical Center advised 936 former hospital patients to be tested for hepatitis C. An investigation revealed they may have been exposed to the disease through the actions of a former ...
The Columbian - Mon, 18 Aug 2014 05:56
|Achillion's hepatitis C drug shows promise in trial|
(Reuters) - Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. The mid-stage trial tested Achillion's ...
Reuters - Fri, 15 Aug 2014 06:00
|Achillion rises on hepatitis C drug study|
Businessweek - Fri, 15 Aug 2014 05:56
|Achillion's Hepatitis C Drug Cures All Patients In Mid-stage Trial|
Business Insider - Fri, 15 Aug 2014 05:56
|Achillion One Step Closer To Billion Dollar HCV Market|
Bidness Etc - Fri, 15 Aug 2014 06:52
|Why Achillion Pharmaceuticals, Inc. Stock Soared|
Motley Fool - Fri, 15 Aug 2014 11:50
|Acute Hepatitis C Rises Among Young People|
An emerging epidemic of acute hepatitis C threatens the country's younger population, which experienced a significant hike in the number of cases during a recent 6 year period, according to a compound study that looked at trends of the disease among ...
HCPLive - Tue, 19 Aug 2014 12:19
|UK Recommends Covering Sovaldi Hepatitis C Pill|
The U.K. agency that evaluates the cost effectiveness of prescription drugs has recommended the government pay for the controversial Sovaldi hepatitis C treatment, although not for all patients. The move, which still requires a final endorsement, comes ...
Wall Street Journal (blog) - Thu, 14 Aug 2014 18:02
|The Competition To Gilead's Hepatitis C Drug Sovaldi|
Bidness Etc - Fri, 15 Aug 2014 05:11
|Gilead beats back Roche, wins U.K. victory for hepatitis C drug Sovaldi|
San Francisco Business Times (blog) - Fri, 15 Aug 2014 08:00
|UK cost body backs pricey Gilead hepatitis pill for some patients|
Reuters - Thu, 14 Aug 2014 16:02
|English Drug Panel Backs Hepatitis Drug at a REBATE|
Angle Chronicle - Sun, 17 Aug 2014 10:37
|Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up|
Zacks.com - Mon, 18 Aug 2014 09:30
|Gilead, Vipshop Lead Top 4 IBD 50 Stocks In EPS Gains GILD VIPS|
Investor's Business Daily - Sat, 16 Aug 2014 05:09
|Merck Is Banking On Pembrolizumab And Hepatitis C Pipeline|
To mitigate this risk, it is developing some promising drugs to treat cancer and hepatitis C. The market for both these diseases is significant and the industry is witnessing strong R&D efforts from big pharma companies in this area at present. While ...
Forbes - Wed, 13 Aug 2014 05:37
|Vertex to stop selling hepatitis C drug Incivek|
In a move that shows how fast things can change in the biotechnology industry, Vertex Pharmaceuticals Inc. has told doctors it will discontinue sales of Incivek, the hepatitis C treatment that was the first drug developed by the Boston company. Incivek ...
Boston Globe - Tue, 12 Aug 2014 13:55
|Vertex to stop selling hepatitis C drug Incivek, once a blockbuster, in October|
Boston Business Journal (blog) - Tue, 12 Aug 2014 11:45
|From Riches to Rags: Vertex Discontinues Incivek as Sales Evaporate|
Wall Street Journal (blog) - Tue, 12 Aug 2014 07:41